Hepatitis C: a clinical review
AA Modi, TJ Liang
The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Hepatitis C is a major cause of chronic liver disease. It has been recognized as a global health problem because of the progression to cirrhosis and hepatocellular cancer.
Chronic hepatitis C is usually asymptomatic but can cause considerable liver damage before its recognition.
This review discusses the natural history, clinical features, diagnosis, therapy, treatment responses and the side effects associated with the treatment of hepatitis C.
Oral Diseases (2008) 14, 10–14
Keywords: natural history; therapy; genotype; peginterferon;
About 170 million people in the world are infected with hepatitis C virus (HCV). Since the discovery of HCV in 1989 (Alter et al, 1999), the number of acute HCV cases has fallen by more than 80% (Wasley and Alter, 2000).
However, hepatitis C is still a major health burden because 60–80% of infected people progress to chronic infection (Di Bisceglie, 2000). HCV is a single-stranded RNA virus belonging to the Flaviviridae family (Lin- denbach and Rice, 2005). The major routes of trans- mission are injection drug use, blood transfusion, hemodialysis, organ transplantation and less frequently sexual intercourse. Six major genotypes (1–6) of HCV have been identiﬁed, and they have varying geographical distribution. Genotypes 1, 2 and 3 are distributed worldwide with genotype 1 accounting for 40–80% of all cases. Genotype 4 is found in the Middle East and Egypt, genotype 5 in South Africa and genotype 6 in South East Asia (Wasley and Alter, 2000).
Hepatitis C virus infection can present as acute or chronic hepatitis. Acute hepatitis usually is asymptom- atic and rarely leads to hepatic failure. Symptomatic
acute HCV has a mild clinical course with <25% of patients presenting with jaundice. About 60–80% people with acute infection develop chronic infection (Hoofna- gle, 2002). The rate of spontaneous viral clearance in patients with chronic HCV is very low. Approximately one ﬁfth (20–30%) of patients with chronic HCV develop cirrhosis over a time period of 10–30 years (Thomas and Seeﬀ, 2005). Several factors may deter- mine the rapidity of disease progression. Some of the well-characterized factors are HCV acquisition at an advanced age (>40–55 years), male sex, HIV co-infec- tion, higher body mass index, presence of hepatic steatosis and consumption of alcohol. Patients with cirrhosis can decompensate with complications. Decom- pensated cirrhosis results in portal hypertension, which can lead to ascites, spontaneous bacterial peritonitis, esophageal varices, neurological complications such as hepatic encephalopathy and hepatic coma, and hepato- renal syndrome leading to renal failure. Chronic infec- tion can also be associated with extra-hepatic manifestations such as cryoglobulinemia, porphyria cutanea tarda, arthralgia, membranoproliferative glomerulonephritis, Sjogren’s syndrome, Raynaud’s syndrome, idiopathic thrombocytopenic purpura and non-Hodgkin’s lymphoma (Liang et al, 2000). Among those with cirrhosis, 1–4% per year develop hepato- cellular carcinoma (Fattovich et al, 2004). Deaths asso- ciated with chronic HCV are usually a result of the complications of decompensated cirrhosis and hepato- cellular carcinoma. Survival rates decline rapidly with the onset of decompensation. The 5-year survival rate for patients with compensated cirrhosis is as high as 90% as compared to 50% for those with decompensated cirrhosis (Fattovich et al, 1997; Hu and Tong, 1999).
Clinical features and diagnostic evaluation Most patients with chronic HCV are asymptomatic or may present with nonspeciﬁc symptoms such as fatigue or malaise. Some of them may have arthralgia and myalgia. Patients with decompensated disease may display peripheral manifestations of cirrhosis, such as palmar erythema, spider nevi, Dupuytren’s contracture, gynaecomastia, parotid enlargement, temporal muscle wasting, ascites, hepatosplenomegaly or testicular
Correspondence: T Jake Liang, MD, NIDDK, NIH, 10 Center Drive, Room 9B-16, Bethesda, MD 20892, USA. Tel: +1 301 496 1721, Fax: +1 301 402 0991, E-mail: Jakel@bdg10.niddk.nih.gov
Received 09 September 2007; accepted 10 September 2007
All rights reserved http://www.blackwellmunksgaard.com
atrophy. The diagnosis of HCV is made by the presence of anti-HCV antibody and HCV RNA in the blood.
Further evaluation includes genotyping and quantifying HCV viral level, which usually is in the range of 0.2)5 million IU ml)1. Basic laboratory tests like liver func- tion tests, prothrombin time and hepatitis B as well as HIV serologies should be performed. Liver biopsy is often useful in making the correct diagnosis and determining the severity of inﬂammation and stage of ﬁbrosis (Kleiner, 2005).
Treatment considerations for hepatitis C are based on the presentation of the disease (acute vs chronic), genotype, laboratory values, presence of co-infection (HIV, hepatitis B) and co-morbidities. The main goal of treatment of HCV is to achieve sustained virologic response (SVR), deﬁned as the absence of HCV RNA in serum at least 6 months after the discontinuation of therapy. The cost of a 48-week treatment ranges from
$30 000 to $40 000 not including the clinic visits during ongoing treatment (Hoofnagle and Seeﬀ, 2006; Shah and Wong, 2006). Hence, every patient should be carefully evaluated with respect to treatment indica- tions, associated co-morbidities, adherence to treatment and reliability of follow-up.
Chronic hepatitis C
Treatment of chronic hepatitis C in adults is recom- mended for those who have detectable HCV RNA levels, elevated aminotransferase (ALT) levels, liver biopsy ﬁndings suggestive of progressive liver disease and the absence of any serious co-morbid conditions or contraindications as listed in Table 1 (Strader et al, 2004; Dienstag and McHutchison, 2006). ALT levels however, do not always correlate with disease severity and hence, treatment should not be denied in those with normal ALT levels (Bacon, 2002).
The therapy of hepatitis C has improved substantially over the years (Figure 1). The current recommended treatment of chronic HCV is the combination of
peginterferon and ribavirin. a-Interferon was ﬁrst shown to have a beneﬁt in chronic hepatitis C infection in 1986 (Di Bisceglie and Hoofnagle, 2002). Five to ﬁfteen percent of patients achieved SVR after a 6- to 12-month course of IFN-a. The overall response rates were substantially increased by the addition of the oral nucleoside analog ribavirin. IFN-a, by activating a variety of antiviral pathways, is active against many RNA viruses including HCV. The mechanism of action of ribavirin is not well understood. It has no direct antiviral activity and appears to enhance the antiviral eﬀect of IFN-a in the treatment of hepatitis C, possible by a combination of mechanisms (Feld and Hoofnagle, 2005).
Another signiﬁcant advance in HCV therapy came with the development of long-acting pegylated inter- feron (peginterferon). A polyethylene glycol moiety is covalently attached to the IFN-a molecule resulting in a product that is still biologically active, but has a larger molecular mass, improved distribution and increased half-life. The combination of peginterferon and ribavirin has been shown to yield the highest response rates in three pivotal trials (Manns et al, 2001; Fried et al, 2002;
Hadziyannis et al, 2004). With peginterferon and riba- virin, 70–80% of patients with genotype 2 or 3 infection and 42–45% of those with genotype 1 infection can achieve a SVR. These results were signiﬁcantly better than those achieved with standard combination therapy or peginterferon monotherapy. The current recom- mended regimen is summarized in Table 2. There is no current established treatment for patients with genotype 4, 5 or 6. These patients are usually treated with the same regimen used for genotype 1 patients (El-Zayadi et al, 2005).
Acute hepatitis C
An optimal treatment regimen for acute hepatitis C has not yet been established. Genotype and HCV RNA levels do not seem to play a role in determining treatment outcomes (Alberti et al, 2002). Up to 50%
of patients with acute HCV spontaneously clear the virus (Gerlach et al, 2003; Hofer et al, 2003). Hence, a delay of treatment for 8–12 weeks after the onset of acute hepatitis C has been suggested. A recent trial
Table 1 Contraindications to treatment with peginterferon and ribavirin
Absolute contraindications 1. Pregnancy
2. Breast feeding
3. Allergic reaction to either drug Relative contraindications
1. Decompensated liver disease as deﬁned by bilirubin >1.5 mg dl)1, prothrombin
time >15 s or INR‡1.7, albumin <3.4 g dl)1, ascites, bleeding esophageal varices, hepatic encephalopathy 2. Neuropsychiatric diseases
3. Coronary artery disease 4. Cerebrovascular disease 5. Renal failure
6. Previous organ transplantation
Close monitoring and dose adjustment might be required in patients with anemia, thrombocytopenia or leucopenia. Patients with renal dysfunction might need adjustment of ribavirin dose.
0 20 40 60 80 100
IFN 6 m IFN 12 m IFN/R 6 m IFN/R 12 m PegIFN 12 m Peg/R low 12 m
Peg/R std 12 m
Sustained response (%)
1980s 1990s 2000s
Figure 1 Progress in therapy of hepatitis C. IFN, interferon; PegIFN, peginterferon; R, ribavirin; R low, low-dose ribavirin; R std, standard- dose ribavirin
AA Modi and TJ Liang
demonstrated >90% SVR rates in individuals with acute HCV when treatment with peginterferon was started within 12 weeks after onset of disease. Both IFN and peginterferon with or without the combination of ribavirin have been used in various studies with prom- ising results. Studies with IFN-a have reported SVR rates of as high as 95% when patients are treated for 24 weeks (Kamal et al, 2006). Similarly, studies of peginterferon with or without ribavirin have reported SVR rates of 80–89% with 24 weeks of treatment (Kamal et al, 2004; Wiegand et al, 2006).
There are three types of response to therapy: SVR, relapse or breakthrough, and non-response. In patients with SVR, HCV RNA levels become undetectable in 4–
24 weeks and remain negative for the entire duration of follow-up. ALT levels return to normal and liver histology shows improvement. In those with relapse (20%), the HCV RNA levels reappear after therapy is stopped, usually within a few weeks of the end of treatment. In those with breakthrough (10%), HCV RNA levels initially become undetectable but reappear during therapy. In patients with non-response, HCV RNA levels never become undetectable during treat- ment. In genotype 1 patients, it is unlikely to achieve SVR if they do not become HCV RNA negative by 24 weeks of therapy (Manns et al, 2001; Hadziyannis et al, 2004). Moreover, if HCV RNA levels do not decrease by 2 log10IU ml)1 or more by 12 weeks of therapy, SVR is unlikely in >98% of cases and therefore therapy should be stopped (Davis, 2002;
McHutchison et al, 2002).
Predictors of treatment response
Various factors have been associated with lower response rates in patients undergoing treatment with peginterferon and ribavirin. They are genotype 1, African American race, pretreatment HCV RNA levels of >800 000 IU ml)1, male sex, higher body mass index and advanced ﬁbrosis (Feld and Hoofnagle, 2005;
Hoofnagle and Seeﬀ, 2006). Hence, these factors should be reviewed when considering therapy.
Adverse effects of treatment
Treatment with peginterferon and ribavirin is associated with numerous adverse eﬀects (Table 3). Most patients
undergoing treatment experience side eﬀects ranging from mild to severe. As a result, patient education of potential side eﬀects as well as monthly visits for monitoring blood counts and symptoms should be emphasized before the initiation of therapy. The most common side eﬀects of peginterferon are fatigue, muscle aches and psychological side eﬀects such as depression, anxiety, irritability and sleep disturbance. These side eﬀects are usually managed in an outpatient setting with patient education, antidepressants⁄anxiolytics, referral to a psychiatrist and the use of erythropoietin or granulocyte macrophage colony stimulating factor if needed. If side eﬀects are not well controlled, dose reduction from 180 lg week)1 to 135 or 90 lg week)1 for peginterferon alfa-2a, and from 1.5 to 1.0 lg kg)1week)1for peginterferon alfa-2b as well as drug discontinuation should be considered (Fried, 2002).
Table 2 Current recommended therapy for chronic hepatitis C
Peginterferon dose (SQ)
Ribavirin dose (PO)
Duration of treatment
(weeks) 1 Peginterferon a-2a:
180 lg week)1 Peginterferon a- 2b:
1.5 lg kg)1week)1
1000 mg day)1for body wt.£ 75 kg 1200 mg day)1for body wt. > 75 kg
2 or 3 Same as above 800 mg day)1 24
Table 3 Adverse eﬀects Adverse eﬀects of
Inﬂuenza like symptoms:
Typically after the ﬁrst injection.
Hair loss: 20–25% of patients,
Bone marrow suppression:
Typically 30–50% reduction in counts, may treat with G-CSF.
CNS toxicity: headache, depression, irritability, psychological changes
10% of patients, use of anti-depressants, dose reduction if severe.
Seizures 1–2% of patients,
Autoimmune thyroid disease:
1–2% of patients, treat if symptomatic.
Others: cardiac side eﬀects, interstitial nephritis,
vision and hearing disturbances, elevation in serum aminotransferases Adverse effects of
Hemolytic anemia Dose reduction if
symptomatic or Hct <30%, dose discontinuation if Hct drops further, may use erythropoietin.
Lymphopenia Lymphocyte counts may
decrease by 10–15%.
Gout: Increase in uric acid Discontinue if attack severe⁄prolonged.
Pruritis 20% of patients,
discontinue if severe.
Nasal stuﬃness, sinusitis 20% of patients, treat if symptomatic.
Teratogenicity Discontinue if pregnancy
Others: Hepatic iron accumulation, cholelithiasis, retinal changes
Hct, hematocrit; G-CSF, granulocyte-colony stimulating factor.
The most common side eﬀect of ribavirin is hemolytic anemia, which usually warrants dose reduc- tion. Around 1–2% of patients on combination therapy experience serious side eﬀects such as myo- cardial infarction in patients with underlying coronary artery disease or stroke in patients with atherosclerotic disease. About 30–40% of patients on 48 weeks of treatment require dose reductions with early discontinuation in up to 20% of patients (Fried et al, 2002; Hadziyannis et al, 2004). Temporary disconti- nuation of ribavirin should also be considered in patients with severe anemia until the hematocrit returns to >30 either with or without the institution of erythropoietin.
Future advances in therapy
Many new approaches to therapy of chronic hepatitis C are being studied in clinical trials. Some of the recent advances have been made in the modiﬁcation of the dose and duration of current recommended com- bination therapy. Ribavirin in high doses (1400–
2400 mg) has been shown to achieve higher SVR rates in a small trial at the expense of a higher toxicity proﬁle (Lindahl et al, 2005). New forms of IFN are being tested clinically. A new generation of small molecule inhibitors targeting the viral-encoded en- zymes, such as the proteases and polymerases is being developed. Many of them are in late phase clinical trials (Pawlotsky, 2007). Although some of them are quite promising in suppressing HCV levels in HCV- infected people, drug resistant mutants emerge rapidly after the initiation of therapy. Therefore they would have to be used in combination with IFN-based therapy.
Treatment of hepatitis C has improved substantially in response rates across all genotypes. However, progress remains to be made to improve the SVR rates for genotype 1 patients as well as relapsers and non- responders. Until the above-discussed new agents pass rigorous scrutiny in clinical trials, the current combina- tion therapy of peginterferon and ribavirin will remain the mainstay treatment of hepatitis C for the next 3–
Alberti A, Boccato S, Vario A, Benvegnu L (2002). Therapy of acute hepatitis C. Hepatology 36(5 Suppl. 1): S195–S200.
Alter MJ, Kruszon-Moran D, Nainan OV et al (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556–562.
Bacon BR (2002). Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36(5 Suppl. 1): S179–S184.
Davis GL (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology 36(5 Suppl. 1): S145–S151.
Di Bisceglie AM (2000). Natural history of hepatitis C: its impact on clinical management. Hepatology 31: 1014–1018.
Di Bisceglie AM, Hoofnagle JH (2002). Optimal therapy of hepatitis C. Hepatology 36(5 Suppl. 1): S121–S127.
Dienstag JL, McHutchison JG (2006). American Gastroenter- ological Association technical review on the management of hepatitis C. Gastroenterology 130: 231–264; quiz 14)17.
El-Zayadi AR, Attia M, Barakat EM et al (2005). Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg- interferon-alpha2b⁄ribavirin or induction-dose interferon- alpha2b⁄ribavirin⁄amantadine: a non-randomized controlled study. Am J Gastroenterol 100: 2447–2452.
Fattovich G, Giustina G, Degos F et al (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463–
Fattovich G, Stroﬀolini T, Zagni I, Donato F (2004).
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl. 1): S35–S50.
Feld JJ, Hoofnagle JH (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967–972.
Fried MW (2002). Side eﬀects of therapy of hepatitis C and their management. Hepatology 36(5 Suppl. 1): S237–S244.
Fried MW, Shiﬀman ML, Reddy KR et al (2002). Peginter- feron alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
Gerlach JT, Diepolder HM, Zachoval R et al (2003). Acute hepatitis C: high rate of both spontaneous and treatment- induced viral clearance. Gastroenterology 125: 80–88.
Hadziyannis SJ, Sette H Jr, Morgan TR et al (2004).
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
Hofer H, Watkins-Riedel T, Janata O et al (2003). Spontane- ous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.
Hepatology 37: 60–64.
Hoofnagle JH (2002). Course and outcome of hepatitis C.
Hepatology 36(5 Suppl. 1): S21–S29.
Hoofnagle JH, Seeﬀ LB (2006). Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355: 2444–2451.
Hu KQ, Tong MJ (1999). The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.
Hepatology 29: 1311–1316.
Kamal SM, Ismail A, Graham CS et al (2004). Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-speciﬁc T cell response kinetics. Hepatology 39: 1721–1731.
Kamal SM, Fouly AE, Kamel RR et al (2006). Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130: 632–638.
Kleiner DE (2005). The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 25: 52–64.
Liang TJ, Rehermann B, Seeﬀ LB, Hoofnagle JH (2000).
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296–305.
Lindahl K, Stahle L, Bruchfeld A, Schvarcz R (2005).
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41: 275–279.
Lindenbach BD, Rice CM (2005). Unravelling hepatitis C virus replication from genome to function. Nature 436: 933–938.
Manns MP, McHutchison JG, Gordon SC et al (2001).
Peginterferon alfa-2b plus ribavirin compared with
AA Modi and TJ Liang
interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:
McHutchison JG, Manns M, Patel K et al (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
Gastroenterology 123: 1061–1069.
Pawlotsky JM (2007). Treatment of hepatitis C: don’t put all your eggs in one basket! Gastroenterology 132: 1611–
Shah BB, Wong JB (2006). The economics of hepatitis C virus.
Clin Liver Dis 10: 717–734.
Strader DB, Wright T, Thomas DL, Seeﬀ LB (2004). Diag- nosis, management, and treatment of hepatitis C. Hepatol- ogy 39: 1147–1171.
Thomas DL, Seeﬀ LB (2005). Natural history of hepatitis C. Clin Liver Dis 9: 383–398, vi.
Wasley A, Alter MJ (2000). Epidemiology of hepatitis C: geographic diﬀerences and temporal trends. Semin Liver Dis 20: 1–16.
Wiegand J, Buggisch P, Boecher W et al (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
Hepatology 43: 250–256.